Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesCytophage Technologies Ltd.

Cytophage Technologies Ltd.

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
None CAD 0.00(0%)
Last update at 2026-11-04T21:00:15.054244Z
Market Cap
4.06M

Momentum Score

…

Cytophage Technologies Ltd., a biotechnology company, engages in the research, development, and commercialization bacteriophage therapies to treat bacterial infections affecting human health, animal health, and food security in Canada. It develops poultry health products under the AviPhage name; food safety products under the PhageFend name; bovine mastitis products under the BoviPhage name; and water-soluble solution for livestock producers under the FarmPhage name. The company is headquartered in Oak Bluff, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.03
Low
0.40
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Cytophage Technologies Ltd. develops bacteriophage-based therapies and microbial control products aimed at treating antibiotic-resistant bacterial infections and reducing contamination. Long-term growth drivers include rising global antimicrobial resistance, potential regulatory acceptance of phage therapeutics, and the scalability of phage manufacturing and formulation platforms, which may support future commercial opportunities and partnerships for a differentiated antimicrobial approach.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-
ROE
-171.06%
Net Debt
-
ROCE
-121.15%
Diluted EPS TTM
-0.08

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -7.86M -4.64M -0.71M -3.24M
Net income -7.86M -4.64M -0.71M -3.24M
Selling general administrative 4.30M 3.89M 0.71M 2.85M
Reconciled depreciation 0.71M 0.51M 0.36M 0.30M
Operating income -5.15M -4.59M -0.79M -3.20M
Interest expense 0.10M 0.03M 0.02M 0.03M
Interest income 0.14M 0.00M 0.09M -
Net interest income 0.04M -0.03M 0.09M -0.03M
Total revenue 0.00M 0.00M 0.00M 0.00M
Total operating expenses 5.15M 4.59M 0.79M 3.20M
Total other income expense net -2.75M -0.01M -0.04M -
Net income from continuing ops -7.86M -4.64M -0.71M -3.24M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 4.94M 5.44M 3.69M 5.83M
Total liab 2.01M 5.07M 0.24M 0.28M
Total stockholder equity 2.93M 0.37M 3.45M 5.55M
Other current liab - 2.50M - -
Capital stock 25.28M 16.18M 15.44M 14.31M
Retained earnings -26.56M -19.09M -14.45M -10.77M
Cash 1.52M 0.03M 2.25M 4.84M
Total current liabilities 0.68M 3.64M 0.24M 0.17M
Short long term debt - 0.03M - -
Total current assets 1.82M 2.95M 2.75M 4.96M
Short term investments - 5.43M - -
Net receivables 0.00M 0.26M 0.00M 0.00M
Accounts payable 0.21M 0.36M 0.11M 0.01M
Non current assets total 3.11M 2.49M 0.94M 0.87M
Capital lease obligations 1.54M 1.77M 0.11M 0.26M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.06M -4.53M -
Net borrowings -0.04M -0.19M -0.15M -0.13M
Total cash from financing activities -0.06M 3.26M 4.41M 6.58M
Net income -7.86M -4.64M -0.71M -3.24M
Change in cash 1.49M -2.21M -0.12M 3.22M
Begin period cash flow 0.03M 2.25M 0.19M 1.62M
End period cash flow 1.52M 0.03M 0.07M 4.84M
Total cash from operating activities -4.77M -2.86M -0.05M -3.03M
Issuance of capital stock 0.00M 0.52M 5.00M 6.59M
Depreciation 0.71M 0.51M 0.36M 0.30M
Change to account receivables 0.25M -0.15M -0.11M 0.00M
Capital expenditures 1.30M 0.16M 0.38M 0.33M
Change in working capital -0.30M 0.43M -0.07M -0.15M
Stock based compensation 0.00M 0.82M 0.67M 0.05M
Other non cash items 2.69M 0.01M 0.07M 0.00M
Free cash flow -6.07M -3.02M -0.05M -3.37M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
SHRX
Sharp Therapeutics Corp.		 -
-%		 1.37 - - - 32.37
NRX
NurExone Biologic Inc.		 -0.01
2.00%		 0.49 - 6.90 - 15.26
MIR
MedMira Inc		 -
-%		 0.06 - - 223.37 -
TTI
Thiogenesis Therapeutics Corp.		 -
-%		 0.63 - - - 15.17

Profile*

Cytophage Technologies Ltd.

Cytophage Technologies Ltd., a biotechnology company, engages in the research, development, and commercialization bacteriophage therapies to treat bacterial infections affecting human health, animal health, and food security in Canada. It develops poultry health products under the AviPhage name; food safety products under the PhageFend name; bovine mastitis products under the BoviPhage name; and water-soluble solution for livestock producers under the FarmPhage name. The company is headquartered in Oak Bluff, Canada.

400 Fort Whyte Way, Oak Bluff, MB, Canada, R4G 0B1

https://cytophage.com

Name Title Year Born
Dr. Steven Theriault B.Sc., M.Sc., Ph.D. CEO, Chief Science Officer & Director NA
Mr. Julius John Kalcevich M.B.A. Chief Financial Officer 1975
Ms. Heather Medwick B.A. Chief Operating Officer NA
Mr. Michael Graham M.B.A. Chief Commercialization Officer 1977
Mr. James F. Kinley C.A., CPA Chief Financial Officer 1978

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 30.50
+15.05%
DSV
CAD 11.02
+14.55%
USA
CAD 4.29
+13.19%
NUAG
CAD 7.70
+12.90%
GMIN
CAD 43.79
+12.86%
DRUG
CAD 26.11
-29.58%
HUT
CAD 68.98
-22.41%
UCU
CAD 2.09
-14.34%
VET
CAD 14.87
-14.29%
PHX
CAD 10.96
-13.56%

Equity Sectors*

  • Basic Materials

    +5.46%

  • Communication Services

    +3.38%

  • Consumer Cyclical

    +3.11%

  • Consumer Defensive

    +1.35%

  • Energy

    -4.79%

  • Financial Services

    +2.66%

  • Healthcare

    -0.72%

  • Industrials

    -0.11%

  • Real Estate

    +1.84%

  • Technology

    +1.05%

  • Utilities

    +0.39%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…